Dishman Pharmaceuticals & Chemicals Ltd. - (Amalgamated) - Stock Valuation and Financial Performance

BSE: 532526 | NSE: DISHMAN | Pharmaceuticals & Drugs | Small Cap

BSE Share Price
Not Listed

DeciZen - make an informed investing decision on Dishman Pharma(Amalg

M-Cap below 100cr DeciZen not available

Dishman Pharmaceuticals & Chemicals Ltd. - (Amalgamated) stock performance -

mw4me loader
P/E Ratio (SA):
74.11
Market Cap:
4,858.8 Cr.
52-wk low:
278.1
52-wk high:
304.3

Is an attractive stock to invest in?

1. Is a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Dishman Pharmaceuticals & Chemicals Ltd. - (Amalgamated) is a average quality company.

2. Is undervalued or overvalued?

No data found

3. Is a good buy now?

No data found

10 Year X-Ray of Dishman Pharma(Amalg:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Dishman Pharmaceuticals & Chemicals Ltd. - (Amalgamated) has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good

Value Creation

Value Creation Index Colour Code Guide

Mar'07Mar'08Mar'09Mar'10Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16TTM
ROCE % 11.5%10.2%15.5%9.5%6%7.7%8.6%10.4%7.2%8.8%-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 275359416353421463485473492510417
Sales YoY Gr.-30.5%15.8%-15.2%19.3%10.1%4.6%-2.3%4%3.7%-
Adj EPS 3.83.76.34.32.43.24.15.33.35.24.1
YoY Gr.--1.9%71.5%-32.7%-43.2%31%30.3%28.3%-38.1%59.2%-
BVPS (₹) 18.528.33437.839.641.644.849.351.756.4295.5
Adj Net
Profit
54.258.910268.839.151.166.785.65384.266
Cash Flow from Ops. 21.242.590.811011825028.312614.5125-
Debt/CF from Ops. 14.16.23.244.8218.54.243.45-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 7.1%3.9%1.7%3.7%
Adj EPS 3.7%16.6%8.1%59.2%
BVPS13.2%7.3%7.9%9%
Share Price - - - -

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'07Mar'08Mar'09Mar'10Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16TTM
Return on
Equity %
24.616.320.311.86.27.89.511.26.59.62.3
Op. Profit
Mgn %
25.725.636.133.32433.43637.230.133.532.5
Net Profit
Mgn %
19.716.424.619.59.31113.818.110.816.515.7
Debt to
Equity
1.10.60.50.70.90.70.70.70.80.7-
Working Cap
Days
325307270347417436406467564638287
Cash Conv.
Cycle
183168133101796153508591118

Recent Performance Summary

No data to display

Return on Equity has declined versus last 3 years average to %

Sales growth has been subdued in last 3 years %

Net Profit has been subdued in last 3 years %

Sales growth is not so good in last 4 quarters at %

Latest Financials - Dishman Pharmaceuticals & Chemicals Ltd. - (Amalgamated)

Standalone Consolidated
TTM EPS (₹) 4.1 10
TTM Sales (₹ Cr.) 417 1,609
BVPS (₹.) 295.5 103.5
Reserves (₹ Cr.) 4,737 1,638
P/BV 1.02 2.91
PE 74.11 30.15
From the Market
52 Week Low / High (₹) 278.10 / 304.30
All Time Low / High (₹) 16.25 / 346.25
Market Cap (₹ Cr.) 4,859
Equity (₹ Cr.) 32.3
Face Value (₹) 2
Industry PE 47.8

Management X-Ray of Dishman Pharma(Amalg:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *35.7630.3117.2611.462.462.420.570.570.570.00
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Dishman Pharma(Amalg

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'07Mar'08Mar'09Mar'10Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16
Sales275.24359.20415.88352.61420.82463.40484.64473.29492.24510.39
Operating Expenses 204.53272279.48235.34320.13318.52315.49297.07344.07339.61
Manufacturing Costs31.6234.9041.3442.584244.8649.2342.2349.1853.81
Material Costs133.21183.82172.05138.15210.45195.22179.20175.72213.84194.50
Employee Cost 18.0524.6025.2828.6447.1045.2258.2158.3858.8865.89
Other Costs 21.6428.6840.8125.9720.5933.2128.8520.7422.1725.41
Operating Profit 70.7287.20136.40117.27100.69144.88169.14176.21148.17170.78
Operating Profit Margin (%) 25.7%24.3%32.8%33.3%23.9%31.3%34.9%37.2%30.1%33.5%
Other Income 16.0111.995.4012.6916.3911.8413.6355.9867.9162.38
Interest 7.699.7626.9629.9140.5357.5452.7469.2268.1368.66
Depreciation 14.2416.8219.7920.6428.0131.6635.3444.1344.1344.25
Exceptional Items 0000000000
Profit Before Tax 64.8072.6195.0679.4148.5467.5294.70118.84103.82120.25
Tax 2.8911.232.509.048.4122.6831.5232.0545.3433.10
Profit After Tax 61.9161.3892.5670.3740.1244.8463.1886.7958.4887.15
PAT Margin (%) 22.5%17.1%22.3%20.0%9.5%9.7%13.0%18.3%11.9%17.1%
Adjusted EPS (₹)4.33.95.74.42.52.83.95.43.65.4
Dividend Payout Ratio (%)12%13%10%14%24%22%15%11%28%19%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'07Mar'08Mar'09Mar'10Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16

Equity and Liabilities

Shareholders Fund 269.24453.79553.62612.96641.38673.63725.41797.08836.43911.50
Share Capital 14.4415.9416.1416.1416.1416.1416.1416.1416.1416.14
Reserves 254.79437.85537.48596.82625.24657.49709.28780.94820.29895.36
Minority Interest0000000000
Debt298.45262.51290.52434.06488.55429.69459.04416.46505.55542.51
Long Term Debt298.45262.51290.52434.06308.91301.68274.53239.74242.96274.43
Short Term Debt0000179.65128.01184.51176.72262.59268.08
Trade Payables40.6446.2722.9275.06119.0184.9395.2783.6399.5976.10
Others Liabilities 8062.6643.7358.67228.53253.43219.33259.65376.51344.54
Total Liabilities 688.33825.22910.791,180.761,477.471,441.681,499.051,556.811,818.081,874.65

Fixed Assets

Gross Block259.78326.33358.73464.18624.64639.35886.14942.27986.481,006.35
Accumulated Depreciation54.7070.7090.13110.34137.86169.02203.59247.65292.86336.72
Net Fixed Assets205.08255.63268.60353.84486.77470.32682.55694.61693.62669.63
CWIP 49.10110.62172.96267.64198.96257.3448.799.8610.1522.14
Investments 131.29132.51156.37181.99187.14187.06187.06187.06210.16250.78
Inventories98.65120.63116.3299.75124.25119.13127.76133.86171.90145.37
Trade Receivables120.72111.5061.5570.24126.9796.4662.7969.4297.6587.87
Cash Equivalents 4.954.493.204.284.316.4510.8911.2622.629.27
Others Assets78.5389.85131.78203.01349.07304.92379.21450.75611.98689.59
Total Assets 688.33825.22910.791,180.761,477.471,441.681,499.051,556.811,818.081,874.65

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'07Mar'08Mar'09Mar'10Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16
Cash Flow From Operating Activity 21.1742.4590.83109.64117.89249.7228.29125.7014.51124.94
PBT 64.8072.6195.0679.4148.5467.5294.70118.84103.83120.25
Adjustment 15.6413.3647.1540.5454.1777.1780.4754.1454.2253.35
Changes in Working Capital -54.01-35.08-41.315.7324.94112.61-130.57-22.21-112.68-7.77
Tax Paid -5.18-8.36-9.94-17.14-9.75-7.59-16.30-25.06-30.86-40.89
Cash Flow From Investing Activity -194.49-118.98-100.51-213.69-190.76-52.265.67-47.54-35.81-30.22
Capex -80.03-128.86-79.65-196.89-197.22-43.7411.84-92.93-59.21-38.83
Net Investments -119.267.2300.0500.96003.020
Others 4.792.65-20.86-16.856.47-9.48-6.1745.3920.388.61
Cash Flow From Financing Activity 54.2376.078.39105.1372.89-195.32-29.84-78.4425.37-102.44
Net Proceeds from Shares 0000000000
Net Proceeds from Borrowing 000162.7037.33-66.47-59.251019.38-5.94
Interest Paid -6.11-9.76-31.69-33.14-39.97-55.13-52.52-69.39-68.55-69.73
Dividend Paid -4.82-7.63-8.07-9.68-9.68-9.68-9.68-9.68-9.68-32.27
Others 65.1693.4648.16-14.7485.22-64.0391.61-9.3684.225.50
Net Cash Flow -119.08-0.46-1.291.080.032.144.12-0.284.07-7.72
PARTICULARSMar'07Mar'08Mar'09Mar'10Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16
Ratios
ROE (%)28.4417.118.512.136.426.849.0511.437.179.99
ROCE (%)14.1112.8815.7111.67.9310.5912.2514.6512.3512.57
Asset Turnover Ratio0.460.490.490.340.320.320.330.310.290.28
PAT to CFO Conversion(x)0.340.690.981.562.945.570.451.450.251.43
Working Capital Days
Receivable Days1281157567848759506166
Inventory Days119109102110969592100112112
Payable Days1038673129168191184186156165

Dishman Pharmaceuticals & Chemicals Ltd. - (Amalgamated) Stock News

Dishman Pharmaceuticals & Chemicals Ltd. - (Amalgamated) FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Dishman Pharma(Amalg on 01-Jan-1970 05:30 is ₹0.00.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 01-Jan-1970 05:30 the market cap of Dishman Pharma(Amalg stood at ₹4,858.8.
The latest P/E ratio of Dishman Pharma(Amalg as of 01-Jan-1970 05:30 is 74.11.
The latest P/B ratio of Dishman Pharma(Amalg as of 01-Jan-1970 05:30 is 1.02.
The 52-week high of Dishman Pharma(Amalg is ₹304.3 and the 52-week low is ₹278.1.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Dishman Pharma(Amalg is ₹416.8 ( Cr.) .

About Dishman Pharmaceuticals & Chemicals Ltd. - (Amalgamated)

Dishman Pharmaceuticals and Chemicals Limited (DPCL) was incorporated in 1983 as a research-oriented company. Later in 1989 the company started production of a range of phase transfer catalysts and quaternary ammonium and phosphonium compounds. The company became a global market leader and earned the status of the “Quat Company”. In the period of 10 years the production capacity was increased from 10MT per annum to 1500 Mt per annum.

In the year 1995, the company entered into a joint ventured with Schütz & Co, Germany and formed Schütz Dishman Biotech. This company manufactures Chlorhexidine Base, Chlorhexidine HCl, Chlorhexidine Acetate and Chlorhexidine Gluconate solution to cater European market. In 1995-96, the company expanded its activities for the development of many intermediates and APIs. In 1998 in order to penetrate in European and US market, the company formed two wholly-owned subsidiaries Dishman Europe and Dishman USA Inc. In 1998, the company forayed into contract research and manufacture sector. Within a period of 5 years DPCL was able to several contract research and manufacturing projects and later emerged as India’s leading CMO organization (Contract Manufacturing Outsourcing).

Headquartered at Ahmedabad, the company owns three manufacturing units, two located at Bavla and one at Naroda. Presently the company is manufactures a range of Bulk APIs, Intermediates, Specialties and Quats. The company has representative office located at Germany, Italy and Turkey.

DPCL is engaged in the manufacture of active pharmaceutical ingredients (APIs) intermediates. The Company operates in two segments: contract research and contract manufacturing (CRAMS), and bulk drugs, intermediates, quats and specialty chemicals. It provides a range of products to the global market, including a range of reagents, specialty chemicals, APIs and their intermediates.

Business units:

Dishman Specialty Chemicals, which manufactures Phase Transfer Catalysts;

Dishman Vitamins and Chemicals, which manufactures Vitamin D2, Vitamin D3, Vitamin D analogues, cholesterol and laolin related products for pharmaceutical, cosmetic and related markets,

Dishman Disinfectants, which manufactures antiseptic and disinfectant formulations.

The products manufactured by the company include bulk drugs, phase transfer catalyst and fine chemicals

 

Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.